Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

The study assessed the comparative efficacy of zanubrutinib vs acalabrutinib in patients with R/R MCL, in the absence of head-to-head clinical trials, using population-adjusted indirect treatment comparison via simulated treatment comparison approach. Data source for the efficacy of zanubrutinib was informed by the pooled individual patient-level data from 2 clinical trials: BGB-3111-206 (NCT03206970) and BGB-3111-AU-003 (NCT02343120). The efficacy of acalabrutinib was informed by the published aggregated data of the ACE-LY-004 trial (NCT02213926).